These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 25023889)

  • 1. Cost-effectiveness of programs to eliminate disparities in elderly vaccination rates in the United States.
    Michaelidis CI; Zimmerman RK; Nowalk MP; Smith KJ
    BMC Public Health; 2014 Jul; 14():718. PubMed ID: 25023889
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estimating the cost-effectiveness of a national program to eliminate disparities in influenza vaccination rates among elderly minority groups.
    Michaelidis CI; Zimmerman RK; Nowalk MP; Smith KJ
    Vaccine; 2011 Apr; 29(19):3525-30. PubMed ID: 21406266
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of a program to eliminate disparities in pneumococcal vaccination rates in elderly minority populations: an exploratory analysis.
    Michaelidis CI; Zimmerman RK; Nowalk MP; Smith KJ
    Value Health; 2013; 16(2):311-7. PubMed ID: 23538183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pneumococcal Vaccination Strategies in 50-Year-Olds to Decrease Racial Disparities: A US Societal Perspective Cost-Effectiveness Analysis.
    Altawalbeh SM; Wateska AR; Nowalk MP; Lin CJ; Harrison LH; Schaffner W; Zimmerman RK; Smith KJ
    Value Health; 2024 Jun; 27(6):721-729. PubMed ID: 38462225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of pneumococcal and influenza vaccination standing order programs.
    Lin CJ; Zimmerman RK; Smith KJ
    Am J Manag Care; 2013 Jan; 19(1):e30-7. PubMed ID: 23379777
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of influenza vaccination disparities on elderly mortality in the United States.
    Fiscella K; Dressler R; Meldrum S; Holt K
    Prev Med; 2007 Jul; 45(1):83-7. PubMed ID: 17481720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of vaccination against invasive pneumococcal disease among people 50 through 64 years of age: role of comorbid conditions and race.
    Sisk JE; Whang W; Butler JC; Sneller VP; Whitney CG
    Ann Intern Med; 2003 Jun; 138(12):960-8. PubMed ID: 12809452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-Effectiveness of the 4 Pillars Practice Transformation Program to Improve Vaccination of Adults Aged 65 and Older.
    Smith KJ; Zimmerman RK; Nowalk MP; Lin CJ
    J Am Geriatr Soc; 2017 Apr; 65(4):763-768. PubMed ID: 28024090
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccination Program in Chronic Obstructive Pulmonary Disease Patients Aged 50+ Years in Spain.
    Rodríguez González-Moro JM; Menéndez R; Campins M; Lwoff N; Oyagüez I; Echave M; Rejas J; Antoñanzas F
    Clin Drug Investig; 2016 Jan; 36(1):41-53. PubMed ID: 26547199
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of pneumococcal polysaccharide vaccine among healthcare workers during an influenza pandemic.
    Smith KJ; Raymund M; Nowalk MP; Roberts MS; Zimmerman RK
    Am J Manag Care; 2010 Mar; 16(3):200-6. PubMed ID: 20225915
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic evaluation of standing order programs for pneumococcal vaccination of hospitalized elderly patients.
    Middleton DB; Lin CJ; Smith KJ; Zimmerman RK; Nowalk MP; Roberts MS; Fox DE
    Infect Control Hosp Epidemiol; 2008 May; 29(5):385-94. PubMed ID: 18521990
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of dual influenza and pneumococcal vaccination in 50-year-olds.
    Smith KJ; Lee BY; Nowalk MP; Raymund M; Zimmerman RK
    Vaccine; 2010 Nov; 28(48):7620-5. PubMed ID: 20887828
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retrospective cost-effectiveness of the 23-valent pneumococcal polysaccharide vaccination program in Australia.
    Chen C; Beutels P; Wood J; Menzies R; MacIntyre CR; McIntyre P; Newall AT
    Vaccine; 2018 Oct; 36(42):6307-6313. PubMed ID: 30213457
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of 13-valent pneumococcal conjugate vaccine (PCV13) in older Australians.
    Dirmesropian S; Wood JG; MacIntyre CR; Beutels P; McIntyre P; Menzies R; Reyes JF; Chen C; Newall AT
    Vaccine; 2017 Aug; 35(34):4307-4314. PubMed ID: 28693751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of dual influenza and pneumococcal vaccination among the elderly in Shenzhen, China.
    Chen D; Ye Z; Pi Z; Mizukami S; Aoyagi K; Jiang Y
    Vaccine; 2021 Apr; 39(16):2237-2245. PubMed ID: 33757667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness analysis of infant universal routine pneumococcal vaccination in Malaysia and Hong Kong.
    Wu DB; Roberts C; Lee VW; Hong LW; Tan KK; Mak V; Lee KK
    Hum Vaccin Immunother; 2016; 12(2):403-16. PubMed ID: 26451658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Could a federal program to promote influenza vaccination among elders be cost-effective?
    Patel MS; Davis MM
    Prev Med; 2006 Mar; 42(3):240-6. PubMed ID: 16480761
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors associated with vaccination of medicare beneficiaries in five U.S. communities: Results from the racial and ethnic adult disparities in immunization initiative survey, 2003.
    Winston CA; Wortley PM; Lees KA
    J Am Geriatr Soc; 2006 Feb; 54(2):303-10. PubMed ID: 16460383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of an influenza vaccination program offering intramuscular and intradermal vaccines versus intramuscular vaccine alone for elderly.
    Leung MK; You JH
    Vaccine; 2016 May; 34(22):2469-76. PubMed ID: 27079928
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pneumococcal Vaccination in Adults Aged ≥65 Years: Cost-Effectiveness and Health Impact in U.S. Populations.
    Wateska AR; Nowalk MP; Lin CJ; Harrison LH; Schaffner W; Zimmerman RK; Smith KJ
    Am J Prev Med; 2020 Apr; 58(4):487-495. PubMed ID: 32001052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.